ArticleCureus2025
Resolution of Ascending Aorta and Pulmonary Vein Thrombi With Apixaban Therapy: A Case Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Article
- Dabigatran and Edoxaban in the Repair of an Abnormal Cleft in the Right Wall of the Ascending Aorta: A Case Report.Cureus · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate ascending aorta (AAo) thrombi and the effects of apixaban using transesophageal echocardiography (TEE) and cardiac computed tomography (CT).
introductionStudies of thrombi retrieved from acute ischemic stroke (AIS) patients revealed that those thrombi contained collagen and calcifications, indicating that the thrombi were chronic or old. These patients had chronic thrombi before AIS occurred, and some of the thromboemboli could separate from chronic thrombi and cause AIS. Left atrial appendage (LAA) thrombi in atrial fibrillation (AF) patients are candidates for such chronic thrombi; however, patients without LAA thrombi may have an AIS. Where do those thrombi come from? In prior reports, we described several cases of pulmonary vein thrombi (PVTs), which can cause AIS and acute myocardial infarction (AMI) by separating large clots. We found other candidates in the AAo. We found that a reduced dose of apixaban partially resolved AAo thrombi. PATIENT PRESENTATION: A 73-year-old male with hypertension was examined using cardiac CT and TEE to detect AAo thrombi and PVTs. The patient was treated with apixaban.
resultsTEE revealed white thrombi with surrounding dark thrombi on the right side in the AAo, and the white thrombi seemed to connect to white right upper pulmonary vein (RUPV) thrombi through line-like white thrombi. A reduced dose of apixaban (2.5 mg; twice daily) was used because the dose reduction weight criteria were met and resolved most AAo thrombi; however, the decreased dose of apixaban (2.5 mg; once a day) was not able to prevent AAo thrombi from regrowing. DISCUSSION: TEE demonstrated that RUPV thrombi, seemingly contacting line-like white thrombi, and thrombi in the AAo were affected by apixaban. Line-like white thrombi looked to approach the wall of the AAo, and approaching areas looked like a mass; the wall of the AAo could not be clearly identified. How the wall was affected is unknown and could be associated with leukocytes such as monocytes, macrophages, and myofibroblasts present in white thrombi with shadows around the ostia of the RUPV.
conclusionWhite RUPV thrombi approached AAo thrombi through white line-like thrombi. These thrombi were partially resolved by treatment with a reduced dose of apixaban; however, the positive effect diminished with decreasing dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.